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ABSTRACT
Background: Magic TouchTM is a sirolimus-based nano-carrier 
eluting balloon. This study aimed to find the excipient:drug ratio 
with the greatest capacity to inhibit neointimal proliferation 
28 days after the use of this balloon and following bare-metal 
stenting in porcine coronary arteries. Methods: Fourteen domestic 
pigs who received coronary bare-metal stent implants followed 
by dilation (60 seconds) using balloons with excipient:sirolimus 
ratios of 1:1, 0.5:1, 0.25:1, and 1:0 or a control balloon were 
evaluated. After 28 days, neointimal hyperplasia was assessed 
by optical coherence tomography and histopathology. Results: 
The rate of neointimal hyperplasia as assessed by optical co-
herence tomography and histomorphometry was 32.2% and 
35.1%, 28.1% and 33.4%, 17.3% and 20.9%, 28.6% and 
30.2%, and 37.9% and 42.3% in the 0.25:1, 0.5:1, 1:1, and 
1:0 excipient:sirolimus ratio groups and the control balloon 
group, respectively (P = 0.03 for excipient:sirolimus 1:1 versus 
control balloon). The neointimal interstrut thickness (mm) was 
0.23, 0.30, 0.16, 0.24, and 0.30 in the 0.25:1, 0.5:1, 1:1, 
and 1:0 excipient:sirolimus ratio groups and the control bal-
loon group, respectively (P < 0.01 for excipient:sirolimus 1:1 
versus control balloon). The inflammation, injury, and fibrin 
deposition scores were low, and there were no significant dif-
ferences among the groups. Conclusions: There was a stepwise 
increase in the inhibitory efficacy of neointimal proliferation 
as the excipient concentration increased. The lowest efficacy 
was observed with the 0.25:1 excipient:sirolimus formula-
tion, and the greatest inhibition was observed with the 1:1 
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RESUMO
Estudo da Dose Excipiente:Fármaco com Avaliação da 
Hiperplasia Neointimal por Tomografia de Coerência 
Óptica e Histopatologia em Artérias Coronárias 
Porcinas após o Emprego do Balão Eluidor de Sirolimus
Introdução: Magic TouchTM é um balão recoberto com nano-
partículas carreadoras de sirolimus. Objetivamos encontrar a 
dose excipiente:fármaco com a maior capacidade de inibição 
da proliferação neointimal 28 dias após o uso desse balão 
pós-implante de stent não farmacológico em artérias coronárias 
porcinas. Métodos: Foram avaliados 14 porcos com implante 
coronário de stent não farmacológico seguido por dilatação 
(60 segundos) com balões com relação excipiente:sirolimus 
1:1, 0,5:1, 0,25:1 e 1:0 ou balão controle. Após 28 dias a 
hiperplasia neointimal foi estudada por tomografia de coerência 
óptica e histopatologia. Resultados: A hiperplasia neointimal 
porcentual (%) avaliada pela tomografia de coerência óptica e 
pela histomorfometria foi de 32,2 e 35,1, 28,1 e 33,4, 17,3 e 
20,9, 28,6 e 30,2, e 37,9 e 42,3 nos grupos excipiente:sirolimus 
0,25:1, 0,5:1, 1:1, 1:0 e balão controle, respectivamente 
(P = 0,03 para excipiente:sirolimus 1:1 vs. balão controle). A 
espessura (mm) da neoíntima inter-hastes foi de 0,23, 0,30, 
0,16, 0,24 e 0,30 nos grupos excipiente:sirolimus 0,25:1, 
0,5:1, 1:1, 1:0 e balão controle, respectivamente (P < 0,01 
para excipiente:sirolimus 1:1 vs. balão controle). Os escores de 
inflamação, injúria e deposição de fibrina foram baixos e sem 
diferenças significantes entre os grupos. Conclusões: Ocorreu 
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excipient:sirolimus formulation. The 1:1 excipient:sirolimus 
formulation significantly reduced neointimal proliferation 
when compared to the control group, with low inflammation 
and injury scores.
 
 
 
DESCRIPTORS: Angioplasty, balloon, coronary. Coronary 
restenosis. Stents. Sirolimus. Animal studies.
gradual aumento da eficácia inibitória da proliferação neointimal 
à medida que a concentração do excipiente aumentou; a menor 
eficácia ocorreu com a formulação excipiente:sirolimus 0,25:1 
e a mais intensa inibição foi observada com a formulação 
excipiente:sirolimus 1:1, a qual reduziu significantemente a 
proliferação neointimal em comparação com o grupo controle, 
com baixos índices de inflamação e injúria.
DESCRITORES: Angioplastia coronária com balão. Reestenose 
coronária. Stents. Sirolimo. Experimentação animal.
D rugs with antiproliferative properties, such as paclitaxel and drugs from the ‘limus’ family (si-rolimus, everolimus, zotarolimus, biolimus A9, 
and amphilimus), are embedded in metallic stents,1–5 in 
bioabsorbable stents,6 and also in drug-eluting balloons.7
Restenosis after vascular intervention persists, despite 
the enormous advances made with the introduction of 
drug-eluting stents (DES). However, possibly as an effect 
of the retardation of stent endothelialisation and of the 
inflammatory effects arising from the presence of the 
polymers that carry the antiproliferative drugs, these DES 
have directed attention towards previously little known 
entities, such as stent thrombosis.8 Metal stents, both 
drug-eluting and non-eluting, have several limitations, 
such as their use in lesions in very small-diameter ves-
sels, long lesions, or at very distal locations, as well 
as in lesions with pronounced proximal curvature. For 
these cases, alternatives are required.
Part of the solution may be the use of drug-eluting 
bioabsorbable stents, which provide temporary support 
for the vascular wall, minimising the elastic retraction 
and repairing the dissection that occurs with lesion 
dilation, resulting in a significant reduction in neointi-
mal proliferation when combined with antiproliferative 
drugs.9
Drug-eluting balloons are a possible alternative 
for metallic stent adjunct therapy. Several paclitaxel-
eluting balloons are already commercially available. 
These paclitaxel-eluting balloons have been shown 
to be safe and effective in preclinical and clinical 
studies and are especially effective in the treatment 
of intrastent coronary restenosis.10 Clinical studies are 
being performed to evaluate paclitaxel-eluting balloon 
efficacy in treating other coronary lesions, such as those 
located in small-calibre vessels, in chronic occlusions 
or accompanying clinical conditions such as diabetes 
mellitus and acute myocardial infarction.
Sirolimus, similar to paclitaxel and zotarolimus, 
is a drug with lipophilic behaviour and is thus ideal 
for incorporation on the surface of these drug-eluting 
balloons. Furthermore, it is a well-known drug and has 
been well-characterised since 1996, when its clinical 
use as an adjuvant therapy after renal transplantation 
was initiated.11 It was used in the first commercially 
available drug-eluting stent (Cypher®, Cordis Corp. 
– Warren, NJ, USA)12 and was the first drug used to 
coat the DES manufactured in Latin America (Inspiron®, 
Scitech Medical – Goiânia, GO, Brazil).1
The aim of this study was to find the best excipient:drug 
ratio of a sirolimus-based nano-carrier balloon (Magic 
TouchTM, Concept Medical, Inc. – Cleveland, OH, USA) 
without polymer coating for use after bare-metal stent 
implantation in porcine coronary arteries.
METHODS
Ethical aspects
All procedures were planned and performed in 
compliance with the standards of protection and care 
for laboratory animals established in the Ethical Prin-
ciples in Animal Experimentation of the Research and 
Animal Experimentation Support Service of the Instituto 
do Coração, Faculdade de Medicina, Universidade de 
São Paulo, Brazil, as well as in the Guide for the Care 
and Use of Laboratory Animals (Institute of Laboratory 
Animal Resources, Commission on Life Sciences and 
National Research Council, National Academy Press, 
Washington, DC, 1996), and the Ethical Principles in 
Animal Experimentation of the Colégio Brasileiro de 
Experimentação Animal (Brazilian College of Animal 
Experimentation, COBEA).13
Animal model
A total of 14 young domestic female, non-
atherosclerotic pigs from a commercial farm received 
intramuscular premedication (ketamine 3  mg/kg, and 
midazolam 0.5 mg/kg) followed by intravenous infusion 
of thiopental, endotracheal intubation, and mechanical 
ventilation with maintenance of anaesthesia with iso-
flurane. Oxygen saturation was monitored through the 
animal’s tail, and heart rate and rhythm were monitored 
with a cardiac monitor.14
Technical information on nano-carrier  
balloons
Nanoparticles consisting of a phospholipid bilayer 
and different excipient:sirolimus formulations were pre-
pared: 0.25:1, 0.5:1, 1:1, and 1:0. These nanoparticles 
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had a mean diameter of 210 nanometres and were 
applied to the surface of coronary angioplasty balloons 
via a conventional spray technique assisted by inert gas. 
In vitro tests indicated stable coating adhesion to the 
balloons, as well as smooth, regular, uniform surfaces 
without folds or fractures.15,16 These nanoparticles, 
when applied to coronary angioplasty balloons after a 
brief exposure of 60 seconds in the arterial wall, are 
initially found on the endothelial surface, then on the 
middle layer, and finally, at deeper locations in the 
adventitial wall.17
Operative technique
After dissection of the common femoral artery, a 
6-F introducer sheath was inserted under direct vision, 
and 10,000  IU of unfractionated heparin were admin-
istered. Then, a 6-F Judkins right therapeutic catheter 
was introduced (Philips – Eindhoven, the Netherlands) 
and monitored by fluoroscopy via Philips BV Pulsera 
digital angiography equipment (Philips – Eindhoven, 
the Netherlands). Each coronary artery was selectively 
catheterised, and 200 mg of intracoronary nitroglycer-
ine were administered. The angiographic projection of 
choice for both the left and right coronary arteries was 
the left anterior oblique at 60 degrees.
After intracoronary passage of a 0.014-inch guide-
wire, cobalt-chromium bare-metal stents (CronusTM, Sci-
tech – Goiânia, GO, Brazil) were implanted according 
to an expanded balloon diameter:artery ratio of 1.1:1. 
The animals, according to previous randomisation, 
were selected to receive one stent per artery and a 
drug-eluting balloon (four different formulations) or a 
conventional balloon per stent. Thus, the 14 animals 
underwent 35 treatments (seven balloons with a 0.25:1 
formulation, seven balloons with a 0.5:1 formulation, 
seven balloons with a 1:1 formulation, seven balloons 
with a 1:0 formulation, and seven conventional bal-
loons). Each stent was dilated for 60 seconds with a 
balloon coated with nanoparticles or with the same 
balloon used for stent release (control group).
After the procedure, the animals were taken to 
pens where they received water ad libitum, commer-
cial feed, and antiplatelet agents (aspirin 100 mg and 
clopidogrel 75 mg) daily for 28 days, when they were 
returned to the lab to be submitted again to coronary 
angiography, optical coherence CT, and subsequently, 
euthanasia.
Coronary angiography control
After the administration of pre-anaesthetic medi-
cation, intubation, inhalation anaesthesia, and the 
administration of intracoronary nitroglycerine, control 
coronary angiographies were performed using the same 
projection used in the index angiographic procedure.
Optical coherence tomography
Immediately after the control coronary angiography, 
optical coherence tomography images were obtained 
using an M2 OCT system (LightLab Imaging – Westford, 
MA, USA).
Initially, a 0.014-inch guidewire was passed 
through the coronary artery distal to the treated site. 
Then, a Helios® balloon (LightLab Imaging) with high 
compliance was introduced over the guide and posi-
tioned distally to the treated site. Then, the 0.014-inch 
guidewire was retreated proximally, and exchanged 
for an ImageWire® catheter (LightLab Imaging). The 
Helios® balloon was retreated proximally, and insuf-
flated with an equivolumetric mixture of saline solution 
and contrast until blood flow occlusion occurred. At 
that moment, saline solution was infused to wash the 
intravascular blood and to obtain optical coherence 
tomography images, followed by an automated retreat 
of the optical coherence tomography image catheter 
at 1  mm/second. These images were analysed to 
determine the presence of thrombus, strut malposi-
tion, and tissue-covering struts, and semiautomated 
measurements were performed of the lumen area, 
the stent area, and the neointimal thickness (distance 
from stent struts to the lumen). The neointimal area 
(stent area minus the lumen area) and the percentage 
of neointimal percentage neointimal area (neointimal 
area divided by the stent area and then multiplied 
by 100) were calculated.
After the optical coherence tomography images 
were obtained, the animals received an additional dose 
of anaesthetic medication, followed by a lethal dose 
of potassium chloride.
After euthanasia, paramedian left thoracotomy and 
pericardiotomy were performed, and the vena cava, the 
pulmonary trunk and the aorta were carefully clamped 
and sectioned, and the heart was removed. The heart 
was then washed with water, and a 10% formaldehyde 
solution was infused under a pressure of 100 mmHg at 
the aortic root for coronary perfusion for 30 minutes. 
The arterial segments containing stents were dissected, 
removed, and placed in a 10% formaldehyde solution 
and sent for histological analysis, as described in a 
previous study.18
Histopathology
Three histological cuts were performed per stent 
segment (proximal, middle, and distal). These sections 
were stained with haematoxylin-eosin, using a Verhoeff 
stain for elastic fibres, and subsequently qualitatively 
and quantitatively analysed by specialised pathologists 
and a technician blinded to the treatment on each slide. 
For the quantitative analysis, the modified inflammation 
scores of Kornovski,19 the fibrin score,20 and the injury 
scores of Schwartz21 and Gunn were used.22
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The measurements of the lumen area, stent area, 
internal elastic lamina area, external elastic lamina area, 
and neointimal thickness on the struts and interstrut 
thickness were performed using Leica Qwin software 
(Leica Microsystems – Wetzlan, Germany).
Statistical analysis
Data are presented as median (minimum-maximum) or 
percentages (%) (minimum-maximum). One-way analysis 
of variance (ANOVA) was used for comparison between 
groups, and post hoc analysis if the variance ratio test 
(F test) was significant. The Statistical Package for Social 
Sciences (SPSS), version 13, was used for data analysis, 
and a P  ≤  0.05 was considered statistically significant.
RESULTS
The 14 animals survived the index procedure up 
to 28 days post-treatment.
During the control angiography, it was observed 
that all coronary arteries were patent and had no im-
ages suggestive of dissection, thrombus, or aneurysm.
Optical coherence tomography
All stents presented complete tissue coating, and 
there were no cases of stent strut malposition.
The implanted stents that were dilated with a sirolimus-
eluting balloon with an excipient:sirolimus formulation of 
1:1 presented lower neointimal area, lower neointimal 
area percentage, and lower neointimal thickness, when 
compared with the control balloon group (1.46 mm2 vs. 
2.16 mm2, 17.3% vs. 32.2%, and 0.15 mm vs. 0.31 mm, 
respectively) (P = 0.03) (Table 1).
Histopathology
Histomorphometric findings
Stents that were dilated with an excipient:sirolimus 
1:1 formulation presented lower neointimal area, lower 
neointimal area percentage, lower neointimal thickness 
on the struts, and lower neointimal interstrut thickness 
as compared to the control balloon group (Table 2).
Histomorphological findings
Low inflammation and fibrin scores were observed 
in all groups, with no significant differences among 
them.
The injury scores (Schwartz and Gunn) were similar 
in all groups, with no significant differences (Table 3).
DISCUSSION
In 2000, Herdeg et al.23 demonstrated that after 
angioplasty in the carotid arteries of rabbits, local 
administration of paclitaxel resulted in a reduction of 
neointimal proliferation area. This resulted in the con-
ception and subsequent development of a new class 
of devices used for percutaneous vascular therapy: the 
drug-eluting balloons.
Scheller et al.,24 in preclinical studies, extensively 
evaluated paclitaxel-coated balloons and observed in a 
clinical study a decrease in the neointimal proliferation 
and efficacy in the treatment of intrastent restenosis.25
In drug-eluting stents, only 15% of the vessel 
surface is in contact with the stent struts, and drug-
eluting balloons have the potential advantage of al-
lowing antiproliferative drug delivery to the arterial 
TABLE 1 
Quantitative Findings of Optical Coherence Tomography
Excipient:sirolimus
0.25:1
(n = 7)
Excipient:sirolimus
0.5:1
(n = 7)
Excipient:sirolimus
1:1
(n = 7)
Excipient:sirolimus
1:0
(n = 7)
Control
balloon
 (n = 7) P
Stent, mm² 7.62 
 (6.53-8.69)
9.36 
 (8.25-11.17)
7.95 
 (7.23-11.26)
8.15 
 (6.74-8.64)
7.89  
(7.33-9.47)
0.4
Lumen, mm² 4.43 
 (3.65-5.83)
6.61 
 (3.59-9.42)
5.96 
 (5.89-9.71)
6.02 
 (3.04-6.52)
4.36  
(3.12-6.22)
0.5
Neointimal  
area, mm²
2.16 
 (2.01-3.85)
2.76 
 (1.57-4.49)
1.46 
 (0.98-2.22)
2.27 
 (1.81-3.62)
2.44  
(1.78-3.70)
0.03*
Neointimal 
area 
percentage, %
32.2 
 (26.6-51.3)
28.1 
 (14.1-66.2)
17.3 
 (12.2-25.1)
28.6 
 (21.7-52.7)
37.9  
(26.6-48.6)
0.03*
Neointimal 
thickness, mm
0.27 
 (0.24-0.49)
0.24 
 (0.19-0.67)
0.15 
 (0.12-0.21)
0.27 
 (0.23-0.48)
0.31  
(0.25-0.53)
0.03*
* Comparison, excipient:sirolimus 1:1 vs. control balloon.
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wall in a broader and more homogeneous manner.26 
Other advantages relative to the bare-metal stents are 
immediate drug release without the use of polymers; 
a potential reduction in the use of antiplatelet agents; 
and the ability to be used in lesions in which stent 
use is not desirable, such as long or distal lesions, 
segments proximal to the lesion that are too angulated, 
small-vessel lesions, bifurcation lesions, lesions in 
peripheral arteries (superficial femoral arteries, pop-
liteal arteries, and other infrapopliteal arteries), and 
haemodialysis shunts. Potentially, these drug-eluting 
balloons can also be used in intravascular lesions in 
paediatric patients. In short, the potential human use 
of drug-eluting balloons will mainly be for all cases 
TABLE 2 
Histomorphometric Findings
Excipient:sirolimus
0.25:1
(n = 7)
Excipient:sirolimus
0.5:1
(n = 7)
Excipient:sirolimus
1:1
(n = 7)
Excipient:sirolimus
1:0
(n = 7)
Control
balloon
 (n = 7) P
Lumen area, 
mm²
3.87
(2.10-4.30)
3.78
(1.71-5.74)
4.30
(3.19-6.25)
3.16
(1.98-4.01)
3.37
(2.32-4.45)
0.7
External 
elastic
lamina, mm²
6.57
(4.81-6.99)
7.88
(6.47-9.27)
6.97
(4.95-8.91)
6.11
(4.99-6.79)
6.94
(5.70-8.58)
0.7
Internal elastic
lamina, mm²
5.37
(3.99-5.86)
6.23
(5.42-7.91)
5.55
(4.01-7.69)
5.01
(3.95-5.58)
5.49
(4.62-6.46)
0.5
Neointimal 
area, mm²
1.44
(1.18-2.03)
2.17
(0.94-4.14)
1.22
(0.83-1.35)
1.59
(1.12-2.14)
1.98
(1.62-2.42)
0.02*
Neointimal 
percentage
area, %
35.1
(25.0-58.9)
33.4
(27.5-78.6)
20.9
(17.4-25.3)
30.2
(24.7-54.2)
42.3
(34.4-46.1)
0.03*
Neointimal 
thickness
on struts, mm
0.21
(0.15-0.47)
0.28
(0.12-0.75)
0.15
(0.13-0.22)
0.22
(0.18-0.24)
0.28
(0.16-0.45)
0.04*
Neointimal
interstrut 
thickness,
mm
0.23  
(0.18-0.46)
0.30  
(0.15-0.74)
0.16  
(0.14-0.21)
0.24  
(0.21-0.24)
0.30  
(0.29-0.47)
0,01*
* Comparison, excipient:sirolimus 1:1 vs. control balloon.
TABLE 3 
Histomorphological Findings 
Excipient:sirolimus
0.25:1
(n = 7)
Excipient:sirolimus
0.5:1
(n = 7)
Excipient:sirolimus
1:1
(n = 7)
Excipient:sirolimus
1:0
(n = 7)
Control
balloon
 (n = 7) P
Inflammation 1 
 (1-1)
1 
 (1-1)
1 
 (0-1)
1  
(1-1)
1  
(1-1)
> 0.9
Fibrin 1 
 (0-1)
1 
 (0.5-1)
1 
 (0-1) 
0 
 (0-0.5)
0 
 (0-1)
0.2
Schwartz 
score
1 
 (0.5-1)
1 
 (1-2)
1 
 (0.5-2)
1 
 (1.5-2)
1 
 (0.5-1)
0.7
Gunn score 2 
 (2-2)
2 
 (1.5-3)
1.5 
 (1.5-2)
2 
 (1-2.5)
1.5 
 (1.5-2)
0.3
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where a stent has limitations or when it is not physi-
cally desirable.
The European Society of Cardiology (ESC) and 
the European Association for Cardio-thoracic Surgery 
(EACTS) recommend the use of paclitaxel-eluting bal-
loons for the treatment of intrastent restenosis, and 
classified them as a class IIa recommendation with 
a B level of evidence.27
Nanotechnology applied to the medical area is 
present in daily practice in materials, equipment, and 
drugs. The encapsulation of drugs through nanoparticles 
allows for the application of several drugs to the sur-
face of balloons and stents and, through them, their 
delivery to tissues.28
The present experimental study de monstrated that 
a balloon covered in sirolimus-eluting nanoparticles 
used after implantation of bare metal stents was safe, 
presenting no evidence of local toxic or thrombotic 
reaction, and that a excipient:drug formulation of 1:1 
significantly inhibited neointimal proliferation in porcine 
coronary arteries.
Clinical studies are necessary to evaluate the safety 
and efficacy in humans and the precise indications for 
sirolimus-eluting balloons in vascular coronary and 
peripheral interventions.
This experimental study was limited by the use 
of animals without atherosclerotic lesions. However, 
for product development purposes, the use of animals 
with normal arteries is accepted and recommended by 
organisations such as the Food and Drug Administra-
tion (FDA).29
Recently published preclinical studies with zo-
tarolimus-releasing balloons30,31 have indicated that the 
‘limus’ family of drugs are promising as antiproliferative 
agents when applied to medical devices.
CONCLUSIONS
In this preclinical experiment using a sirolimus-eluting 
balloon after stent implantation in porcine coronary ar-
teries, a gradual increase in the neointimal proliferation 
inhibitory efficacy of balloon catheters was observed 
when increasing excipient:sirolimus ratios were used. 
The lowest efficacy occurred with an excipient:sirolimus 
formulation of 0.25:1, and the highest occurred with an 
excipient:sirolimus formulation of 1:1, which significantly 
reduced neointimal proliferation when compared with 
the control group. These results were accompanied by 
low levels of inflammation and injury.
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